Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors
02 mai 2023 02h30 HE
|
Medigene AG
Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T...
Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
27 avr. 2023 05h00 HE
|
Medigene AG
Martinsried/Munich, April 27, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs
03 avr. 2023 12h45 HE
|
Medigene AG
Martinsried/Munich, April 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update
29 mars 2023 01h30 HE
|
Medigene AG
Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum continues with a $3...
Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston
28 mars 2023 11h00 HE
|
Medigene AG
Martinsried/Munich, March 28, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
The TCR-based therapies market is projected to be worth around USD 4.4 billion, by 2030, claims Roots Analysis
15 juil. 2021 08h45 HE
|
Roots Analysis
London, July 15, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “TCR-based Therapies Market, 2021-2030” report to its list of offerings. Modified TCR-based adoptive T-cell...